You are here

Article Text

Article menu
Download PDFPDF
Letter
Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey
  1. Corrado Campochiaro1,
  2. Giorgia Trignani1,
  3. Alessandro Tomelleri1,
  4. Stefano Cascinu2,
  5. Lorenzo Dagna1
  6. COVID-19 Vaccine Study Group
    1. 1 Università Vita-Salute San Raffaele, School of Medicine; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
    2. 2 Università Vita-Salute San Raffaele, School of Medicine; Unit of Oncology, IRCCS Ospedale San Raffaele, Milano, Lombardia, Italy
    1. Correspondence to Dr Corrado Campochiaro, Università Vita-Salute San Raffaele, School of Medicine; Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS Ospedale San Raffaele, 20132 Milano, Lombardia, Italy; campochiaro.corrado{at}hsr.it

    https://doi.org/10.1136/annrheumdis-2020-219811

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      Similarly to the general population, advanced age, comorbidities and chronic glucocorticoid treatment (≥10 mg/day prednisone-equivalent) have been identified as negative prognostic factors for COVID-19 also in rheumatological patients.1 2Unfortunately, until today, the only effective recommended strategy to reduce the rate of SARS-CoV-2 infection in rheumatological patients has been the application of preventive life-style measures, such as social distancing and the use of personal protective equipment.3 Hopefully, the recently approved COVID-19 vaccines will revolutionise our approach to the pandemic.4 Although the details of the COVID-19 vaccination plan are yet to be defined in most EU countries, it is expected that rheumatological patients, together with other groups of patients suffering from chronic diseases, will be considered a priority group.5

      To investigate the likelihood of COVID-19 vaccine acceptance, we performed a survey in a cohort of consecutive rheumatological patients followed up at our tertiary referral centre in Milan, Italy. A cohort of patients with neoplastic diseases followed up at the Oncologic Department of the same Institution was included as comparator. All patients provided their informed consent for the use of …

      View Full Text

      Footnotes

      • Handling editor Josef S Smolen

      • Collaborators COVID-19 Vaccine Study Group: Giacomo De Luca, Giulio Cavalli, Luca Moroni, Silvia Sartorelli, Emanuel Della Torre, Elena Baldissera, Nicola Boffini, Giulia Di Colo, Adriana Cariddi, Vanesa Gregorc, Giampaolo Bianchini, Michele Reni, Monica Ronzoni.

      • Contributors CC, GT, AT and the COVID-19 Vaccine Study Group collected the data. AT and CC analysed the data. CC, AT, SC and LD wrote the manuscript.

      • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

      • Competing interests None declared.

      • Provenance and peer review Not commissioned; externally peer reviewed.

      • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.